Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy [PDF]
, 2017 Reslizumab, an anti-interleukin-5 monoclonal antibody, significantly reduces exacerbation frequency and improves lung function, asthma control and quality of life in adults with severe eosinophilic asthma, as demonstrated in Phase III studies.
Brusselle, Guy +4 more
core +3 more sources
CPT: Pharmacometrics & Systems Pharmacology, 2017 Benralizumab is a humanized, afucosylated, anti‐interleukin‐5 receptor α, immunoglobulin G (IgG) 1 κ monoclonal antibody. We developed a population pharmacokinetic (PK)/pharmacodynamic (PD) model for benralizumab by analyzing PK and blood eosinophil ...
B Wang, L Yan, Z Yao, LK Roskos
doaj +1 more source
We Have to Learn to Do Without Knowing Enough: Anti-Eosinophilic Treatments for Severe Asthma [PDF]
, 2018 Interleukin.5 (IL.5) is the main eosinophilic cytokine that promotes the differentiation, survival, and activation of eosinophils, which are the key inflammatory cells in severe eosinophilic asthma .Thus, it is no surprise that ...
4, +3 more
core +1 more source
Anaphylaxis to three humanized antibodies for severe asthma: a case study
Allergy, Asthma & Clinical Immunology, 2020 Background Omalizumab, mepolizumab, benralizumab, and dupilumab are the currently available biologics used to treat asthma in Japan. Anaphylaxis following treatment with mepolizumab or benralizumab is considered rare. Case presentation We report the case
Koichi Jingo +9 more
doaj +1 more source
ERJ Open Research, 2023 Background Benralizumab is highly effective in many, but not all, patients with severe asthma. Baseline characteristics alone are insufficient to predict an individual's probability of long-term benralizumab response.
Johannes A. Kroes +6 more
doaj +1 more source
Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma [PDF]
, 2013 Peer reviewedPublisher ...
Walsh, Garry Michael
core +2 more sources
Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study) [PDF]
, 2021 Publisher Copyright: © 2021, The Author(s).Background: Benralizumab, a monoclonal antibody targeting the human interleukin-5 (IL-5) receptor (IL-5R), was used before marketing authorisation in Spain in a real world setting as part of an early-access ...
ORBE study investigators
core +2 more sources
Personalized medicine with biologics for severe type 2 asthma : current status and future prospects [PDF]
, 2017 Asthma affects more than 300 million people worldwide and poses a large socioeconomic burden, particularly in the 5% to 10% of severe asthmatics. So far, each entry of new biologics in clinical trials has led to high expectations for treating all severe ...
Blanchetot, Christophe +4 more
core +3 more sources
Real-life study of the cost-effectiveness of benralizumab vs previous care in Bulgaria [PDF]
PharmaciaThe aim is to evaluate the cost-effectiveness of benralizumab therapy in real-life settings in Bulgaria in comparison with previous care. The point of view is that of the national health insurance fund, and the time horizon is for one year.
Konstantin Tachkov +2 more
doaj +3 more sources
Molecularly targeted therapies for asthma: current development, challenges and potential clinical translation [PDF]
, 2016 Extensive research into the therapeutics of asthma has yielded numerous effective interventions over the past few decades. However, adverse effects and ineffectiveness of most of these medications especially in the management of steroid resistant severe ...
Lim, Jonathan Chee Woei +3 more
core +1 more source